VYGR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

10.49M

+67.16%

-0.527

-10.63%

9.38M

+44.83%

-0.486

-8.36%

10.80M

+107.74%

-0.443

-22.31%

Estimates Revision

The market is revising Upward the revenue expectations for Voyager Therapeutics, Inc. (VYGR) for FY2025, with the revenue forecasts being adjusted by 18.1% over the past three months. During the same period, the stock price has changed by -23.11%.

Revenue Estimates for FY2025

Revise Upward

+18.1%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.73%

In Past 3 Month

Stock Price

Go Down

-23.11%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast VYGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VYGR is 13.57 USD with a low forecast of 8.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

13.57

High

25.00

Current: 0.000

Low

8.00

Averages

13.57

High

25.00

H.C. Wainwright

Buy

downgrade

$30 -> $25

2025-11-12

Reason

H.C. Wainwright

Price Target

$30 -> $25

2025-11-12

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Voyager Therapeutics to $25 from $30 and keeps a Buy rating on the shares. Voyager reported strong Q3 results, ending the quarter with $229M in cash and operational runway into 2028, while remaining eligible for up to $2.4B in partner milestones, the analyst tells investors in a research note. The company also advanced its NeuroShuttle non-viral delivery technology, with upcoming preclinical and trial data presentations expected to drive potential inflection points, the firm says.

Leerink

Outperform

NULL

downgrade

$12 -> $11

2025-11-10

Reason

Leerink

Price Target

$12 -> $11

2025-11-10

downgrade

Outperform

NULL

Reason

Leerink lowered the firm's price target on Voyager Therapeutics to $11 from $12 and keeps an Outperform rating on the shares. Voyager Therapeutics reported Q3 results and provided pipeline updates, highlighting progress in Alzheimer's programs and its NeuroShuttle nonviral delivery platform, and the company remains on track for key milestones in 2026, including PET imaging data for VY7523 and an IND filing for siRNA therapy VY1706, the analyst tells investors in a research note.

Wedbush

Outperform

NULL

downgrade

$9 -> $8

2025-08-07

Reason

Wedbush

Price Target

$9 -> $8

2025-08-07

downgrade

Outperform

NULL

Reason

Wedbush lowered the firm's price target on Voyager Therapeutics to $8 from $9 and keeps an Outperform rating on the shares. The firm notes the quarterly update reported runway extension from mid-2027 to 2028 with end of Q2 total cash of $262M through restructuring and improving execution efficiency. There appears to be no impact on the pipeline, which in fact was recently further expanded when Voyager announced a fourth wholly owned GTx program that leverages a TRACER capsid to IV-deliver a bifunctional payload to decrease the expression of APOE in APOE4 carriers while increasing the expression of the protective variant APOE2. All other programs remain on track, Wedbush adds.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$30

2025-04-08

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$30

2025-04-08

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$30

2025-03-13

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$30

2025-03-13

Reiterates

Strong Buy

Reason

Canaccord Genuity

Sumant Kulkarni

Strong Buy

Maintains

$14 → $12

2025-03-13

Reason

Canaccord Genuity

Sumant Kulkarni

Price Target

$14 → $12

2025-03-13

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on Voyager Therapeutics to $12 from $14 and keeps a Buy rating on the shares. The firm said they reported its 4Q24 results showing Operating expenses came in at $44.6M versus estimates of $43.0M, and collaboration revenue was $6.3M versus $10.0M estimate. Canaccord believes the delta in both was most likely driven by the timing of R&D activity, which can be difficult to predict.

Valuation Metrics

The current forward P/E ratio for Voyager Therapeutics Inc (VYGR.O) is -2.11, compared to its 5-year average forward P/E of -2.98. For a more detailed relative valuation and DCF analysis to assess Voyager Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.98

Current PE

-2.11

Overvalued PE

-0.43

Undervalued PE

-5.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.05

Current EV/EBITDA

-0.28

Overvalued EV/EBITDA

3.67

Undervalued EV/EBITDA

-5.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.84

Current PS

5.39

Overvalued PS

24.60

Undervalued PS

-2.91

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

VYGR News & Events

Events Timeline

No data

News

9.0

2025-12-03Businesswire

VectorY Receives FDA Clearance to Initiate PIONEER-ALS Trial for VTx-002

9.0

2025-11-25Benzinga

J&J Stops Alzheimer's Study as Drug Proves Ineffective in Slowing Disease Progression

7.5

2025-11-10Newsfilter

Transition Bio and Voyager Team Up to Develop Small Molecules Aiming at TDP-43 for ALS and Frontotemporal Dementia

People Also Watch

Frequently Asked Questions

What is Voyager Therapeutics Inc (VYGR) stock price today?

The current price of VYGR is 4.06 USD — it has decreased -0.73 % in the last trading day.

What is Voyager Therapeutics Inc (VYGR)'s business?

Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.

What is the price predicton of VYGR Stock?

What is Voyager Therapeutics Inc (VYGR)'s revenue for the last quarter?

Voyager Therapeutics Inc revenue for the last quarter amounts to 13.37M USD, decreased -45.73 % YoY.

What is Voyager Therapeutics Inc (VYGR)'s earnings per share (EPS) for the last quarter?

Voyager Therapeutics Inc. EPS for the last quarter amounts to -0.47 USD, increased 193.75 % YoY.

What changes have occurred in the market's expectations for Voyager Therapeutics Inc (VYGR)'s fundamentals?

How many employees does Voyager Therapeutics Inc (VYGR). have?

Voyager Therapeutics Inc (VYGR) has 172 emplpoyees as of January 08 2026.

What is Voyager Therapeutics Inc (VYGR) market cap?

Today VYGR has the market capitalization of 227.13M USD.